ERBB2 and breast cancer: Nevertheless, HER2-positive tumors are relatively more frequent in pregnant patients [7], which may potentially contribute to poorer prognosis; however, similar overall survival (OS) and disease-free survival (DFS) were reported when comparing PABC to non-pregnant breast cancer patients when adjusted for age at diagnosis, stage, grading, histologic tumor type, receptor status, and treatment type [7,9].